NCT00003145 - Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 1997

Primary Completion Date

March 31, 2005

Conditions

Accelerated Phase of DiseaseChildhood Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase of DiseaseRecurrent Disease

Interventions

DRUG

Fludarabine Phosphate

Given IV

RADIATION

Total-Body Irradiation

Undergo TBI

PROCEDURE

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic PBSCT

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic PBSCT

DRUG

Cyclosporine

Given PO or IV

DRUG

Mycophenolate Mofetil

Given PO or IV

BIOLOGICAL

Therapeutic Allogeneic Lymphocytes

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (8)

10126

University of Torino, Torino

75246

Baylor University Medical Center, Dallas

91010

City of Hope Medical Center, Duarte

94305

Stanford University Hospitals and Clinics, Stanford

98101

VA Puget Sound Health Care System, Seattle

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

80217-3364

University of Colorado, Denver

D-04103

Universitaet Leipzig, Leipzig

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER